Xavier Durando
Oncology — Centre Jean Perrin, France
Xavier Durando
LeadR Profile
Oncology
Subspecialties: Neurology - Public Health - Radiotherapy
Main Topics
Publications and Clinical Studies
Organizations
Centre Jean Perrin -
Publications Synthesis
Source: Pubmed
Number : 221
Citations
Main journals
Best Journals
Breakdown by type
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Circulating proteins as biomarkers of response to cancer immunotherapy (Review). cells, lymphocytes, neoplasms, biomarkers, immunotherapy, therapeutics, t-lymphocytes, liquid biopsy | Int J Oncol | 2026 | 0 |
| Patient-reported satisfaction with thermal water-based cosmetic products in breast cancer patients undergoing chemotherapy: a feasibility study. skin, feasibility studies, breast neoplasms, neoplasms, drug therapy, breast, therapeutics, chemotherapy | Cancer Treat Res Commun | 2026 | 0 |
| Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF V600E or BRAF V600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study. progression-free survival, melanoma, neoplasms, drug-related side effects and adverse reactions, immune checkpoint inhibitors, nivolumab, therapeutics, ipilimumab, mutation | Lancet Oncol Top journal | 2025 | 7 |
| Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial. breast neoplasms, neoplasms, drug therapy, aged, drug-related side effects and adverse reactions, chemotherapy, adjuvant, breast, therapeutics, frailty, chemotherapy | Lancet Top journal | 2025 | 1 |
| Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial. cells, confidence intervals, safety, progression-free survival, carcinoma, squamous cell, neoplasms, drug-related side effects and adverse reactions, immune checkpoint inhibitors, vorinostat, therapeutics | Nat Cancer | 2025 | 0 |
Clinical Studies 44
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma NCT06550674 — genes, blood, melanoma, neoplasms, diagnosis, thyroid neoplasms, research, exome, history, wounds and injuries, uveal melanoma | N/A | Recruiting | 2024 |
| Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer NCT05710679 — radiotherapy, blood, tomography, neoplasms, predictive value of tests, positron emission tomography computed tomography, fluorodeoxyglucose f18, chemoradiotherapy, head and neck neoplasms, therapeutics, dna, carcinoma | N/A | Recruiting | 2024 |
| Capecitabine Tucatinib and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease NCT05800275 — injections, meningeal neoplasms, breast neoplasms, spinal puncture, neoplasms, tablets, neoplasm metastasis, breast, punctures, capecitabine, meningeal carcinomatosis, trastuzumab | Phase 2 | Recruiting | 2023 |
| PREventing Second Cancers With DOSTARlimab NCT05855811 — neoplasms, neoplasms, second primary, therapeutics | Phase 2 | Recruiting | 2023 |
| Support and Post therapeutic Rehabilitation for Women in Complete Remission of Breast Cancer in a Thermal Environment NCT05433077 — quality of life, breast neoplasms, neoplasms, rehabilitation, breast, therapeutics, environment, carcinoma, women | N/A | Active not recruiting | 2022 |
LeadR Networks
Main global connection map